Nexeo, being the third largest chemical distributor in the North America, is exposed to double-digit pricing declines in the chemical distribution market.
"We think continued stagnant pricing and weaker demand will weigh on a highly levered (4.4x debt/EBITDA) small-cap name," analyst Andrew Buscaglia wrote in a note.
The analyst noted Nexeo has a much lower margin profile versus peers with a fair amount of catch-up that hinges on market improvement and execution. However, the analyst remains on the sidelines on a recent miss/guidance cut.
"EBITDA guidance of 20 percent y/y growth in 2017 seems ambitious, posing further risk," Buscaglia continued.
However, the cheap valuation provides downside support as NXEO currently trades at 7.8x CS' 2017 EBITDA estimate of $193 million, a discount to peers UNVR and Brenntag at about 10x. That said, the analyst doesn't see the valuation moving any lower at this point, which keeps him Neutral.
Over the long term, the analyst believes the company's investments in to its operations should drive margins as excess capacity is utilized and would benefit from industry consolidation.
"As end markets improve and Nexeo executes, we see potential for long-term multiple expansion," Buscaglia added.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.